Martin A. Lehr
Co-Founder, President, CEO & DirectorMr. Martin A. Lehr serves as Independent Director of Praesidia Biotherapeutics, Inc. He is the Co-founder, President, Chief Executive Officer and Director of Context Therapeutics Inc., since 2015. Mr. Lehr joined the Context Therapeutics Inc. in 2015. He was a Senior Associate at Osage Partners LLC. He joined the firm on August 1, 2009 and was previously an Associate. Mr. Lehr serves on the boards of Praesidia Biologics and CureDuchenne Ventures. Mr. Lehr focused on novel biopharmaceutical products, medical devices, diagnostics and research tools. He was also an Advisor to the University City Science Center’s QED Program and a mentor to the University of Pennsylvania’s Life Science Management program. Mr. Lehr conducted research in the area of DNA repair at the Sloan-Kettering Institute and in thrombin activation at the Children's Hospital of Philadelphia. He serves as a Director of Philly BioBreak and CureDuchenne. He is on the Advisory Board of the Sid Martin Biotech Incubator at the University of Florida. He is a Director of BioBreak. He is an advisory board member of Life Science Cares and Life Science Leader magazine. Mr. Lehr holds an M.A. in Biotechnology from the Columbia University and a B.A. in Economics from the University of Pennsylvania.
Positions
- Company NameContext Therapeutics Inc.Stock CodeCNTXPositionCo-Founder, President, CEO & DirectorColleagues
- APAndrew PasternakIndependent Chairman
- JMJennifer Minai-AzaryCFO & Treasurer
- ACAlex C. LevitChief Legal Officer & Corporate Secretary
- CBChristopher BeckSenior Vice President of Operations
- JLJeffrey LiebmanAssociate Director of Accounting
- JEJennifer Evans StaceyIndependent Director
- LBLinda B. WestIndependent Director
- KLKaren L. SmithIndependent Director
